<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain><z:chebi fb="0" ids="15358">Histone</z:chebi> deacetylase inhibitors (HDACIs) exhibit modest results as single agents in preclinical and clinical studies against <z:e sem="disease" ids="C0280100" disease_type="Neoplastic Process" abbrv="">solid tumors</z:e>; they often fall short and activate nuclear factor kappa-B (NFκB) </plain></SENT>
<SENT sid="1" pm="."><plain>Co-administration of HDACI with <z:chebi fb="0" ids="52726">proteasome inhibitors</z:chebi> (<z:chebi fb="0" ids="53232">PIs</z:chebi>), which interrupt NFκB pathways, may enhance HDACI-<z:mp ids='MP_0010769'>lethality</z:mp> </plain></SENT>
<SENT sid="2" pm="."><plain>The goal of this study was to determine whether <z:chebi fb="0" ids="53232">PIs</z:chebi> could potentiate HDACI, scriptaid (SCP)-mediated <z:mp ids='MP_0010769'>lethality</z:mp>, to unravel the associated mechanisms and to assess the effects of the combined inhibition of HDAC and proteasome on chemotherapy response in human <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e> cells </plain></SENT>
<SENT sid="3" pm="."><plain><z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">Cancer</z:e> cells were exposed to agents alone or in combination; cell growth inhibition was determined by <z:chebi fb="0" ids="53233">MTT</z:chebi> and colony formation assays </plain></SENT>
<SENT sid="4" pm="."><plain>HDAC-, proteasome-, NFκB-activities, and reactive oxygen species (ROS) were quantified </plain></SENT>
<SENT sid="5" pm="."><plain>Induction of <z:mpath ids='MPATH_3'>apoptosis</z:mpath> and cell cycle alterations were monitored by flow cytometry </plain></SENT>
<SENT sid="6" pm="."><plain>Expression of cell cycle/<z:mpath ids='MPATH_3'>apoptosis</z:mpath> and cytoprotective/stress-related genes was determined by real-time qRT-PCR and EIA, respectively </plain></SENT>
<SENT sid="7" pm="."><plain>Potentiation of <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> cell sensitivity to chemotherapies by SCP/<z:chebi fb="0" ids="53232">PIs</z:chebi> was also evaluated </plain></SENT>
<SENT sid="8" pm="."><plain>SCP and <z:chebi fb="0" ids="53232">PIs</z:chebi>: MG132, PI-1, or epoxomicin interact synergistically to potently inhibit <z:e sem="disease" ids="C1516170" disease_type="Neoplastic Process" abbrv="">cancer cell growth</z:e>, alter cell cycle, induce <z:mpath ids='MPATH_3'>apoptosis</z:mpath>, reduce NFκB activity, and increase ROS generation </plain></SENT>
<SENT sid="9" pm="."><plain>These events are associated with multiple perturbations in the expression of cell cycle, <z:mpath ids='MPATH_3'>apoptosis</z:mpath>, cytoprotective, and stress-related genes </plain></SENT>
<SENT sid="10" pm="."><plain>Co-administration of SCP and <z:chebi fb="0" ids="53232">PIs</z:chebi> strikingly increases the chemosensitivity of <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> cells (122-2 × 10(5)-fold) in a drug and SCP/<z:chebi fb="0" ids="53232">PIs</z:chebi>-dependent manner </plain></SENT>
<SENT sid="11" pm="."><plain>This combination regimen markedly reduced the doses of chemotherapies with potent anticancer effects and less toxicity </plain></SENT>
<SENT sid="12" pm="."><plain>A strategy combining HDAC/proteasome inhibition with chemotherapies warrants further investigation in <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e> </plain></SENT>
</text></document>